You can't put a price tag on cancer remission. But initial costs of the first CAR T-cell therapies, Novartis' tisagenlecleucel and Kite Pharma's axicabtagene ciloleucel, were $475,000 and $373,000 respectively. According to an April JAMA Oncology report, those amounts don't include costs associated with leukapheresis, lymphodepletion therapy and treatment for cytokine release syndrome. So, depending on the severity of cytokine release syndrome, tisagenlecleucel could range from $478,777-$531,823. The mean expected cost for axicabtagene ciloleucel is $402,647.